|
|
|
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality
“GSK is the ideal strategic partner for IDEAYA, as this partnership enables compelling potential combinations and the opportunity to build the industry leading Synthetic Lethality pipeline that targets molecularly defined populations in several major solid tumors, including potentially lung, prostate, breast, colorectal, and ovarian cancer,” said Yujiro S. Hata, Chief Executive Officer and President, IDEAYA Biosciences.
|
|
ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron
“This agreement will accelerate the development and commercialization of our lead asset, ISA101b, to treat two important cancers with high unmet medical needs.” commented Gerben Moolhuizen, Chief Executive Officer of ISA Pharmaceuticals. “We are extremely pleased to be working with Regeneron and for their continued support of both ISA Pharmaceuticals and our clinical studies in both indications.”
|
|
Alpine Immune Sciences cuts $865 million licensing deal with Abbvie for its first in class dual CD28/ICOS costimulation antagonist against SLE
Alpine Immune Sciences (Alpine; Seattle & North Chicago), announced a licensing deal with Abbvie on June 18th 2020. Specializing in innovative treatments for autoimmune/ inflammatory diseases, Alpine has developed a first in class dual action molecule, ALPN-101, which is a CD28/ICOS costimulation antagonist. ALP-101 has proved efficacious in preclinical studies with well characterized pharmacokinetics and safety data from adult healthy volunteers. Abbvie has claimed exclusive licensing of the molecule and has paid $60 million in upfront cash, with a potential aggregate payment of $805 million upon completion of success-based development, regulatory and commercial milestones. Additionally, Alpine will received tiered royalties on net sales of ALP-101.
“AbbVie’s expertise in Immunology has led to remarkable breakthroughs in the treatment of autoimmune diseases…ALPN-101’s dual mechanism of action has compelling potential as a next-generation treatment in systemic lupus erythematosus and other autoimmune diseases. We are excited to partner with the team at Alpine on the development of this novel therapeutic.”- Tom Hudson, M.D., Senior Vice President and Chief Scientific Officer, AbbVie.
|
|
Click Here for more news and details on mergers, acquisitions and business updates
|
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|